ArticleNature communications2022
Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 18 citations in OpenAlex.
- Spatially Distinct Bone Marrow Sites Are Asymmetrically Impacted by Inflammatory Cardiovascular Disease.JACC. Basic to translational science · 2026Article
- Myeloid landscape of BRAF-mutant papillary thyroid cancer and thyroiditis.Endocrine-related cancer · 2026Article
- Galectin-9Aging cell · 2026Article
- Immunotherapy in Thyroid Cancer: Current Strategies and Challenges.Cancer medicine · 2026Review
- Microfluidic-based patient-derived organoids recapitulate thyroid cancer heterogeneity and reveal NF-κB-driven maturation for precision therapy.Journal of translational medicine · 2026Article
- Application of XGBoost and logistic regression in predicting 90 days mortality for elderly severe acute renal failure patients.Scientific reports · 2026Article
- Systemically inducing trained immunity overcomes solid tumors' immunosuppressive microenvironment.Science advances · 2026Article
- Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer.Cancer immunology, immunotherapy : CII · 2025Article
- G-CSF/NAMPT signaling drives neutrophil dysfunction and enhances bacterial infection susceptibility in cancer patients.Nature communications · 2025Article
- High Local and Systemic Expression of Pentraxin-3 in Anaplastic Thyroid Cancer.International journal of molecular sciences · 2025Article
- Trained immunity: induction of an inflammatory memory in disease.Cell research · 2025Review
- Thyroid cancer: From molecular insights to therapy (Review).Oncology letters · 2025Review
- Single-Cell RNA Sequencing Reveals the Heterogeneity in Differentiation Trajectory and Tumor Microenvironment Leading to More Aggressive Phenotypes of Papillary Thyroid Cancer in Children and Young Adult Patients.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Single-cell immune aging clocks reveal inter-individual heterogeneity during infection and vaccination.Nature aging · 2025Article
- Review
- Induction of trained immunity in myeloid cells and their progenitors from thyroid cancer patients.Frontiers in immunology · 2025Article
- Polymersomes with splenic avidity target red pulp myeloid cells for cancer immunotherapy.Nature nanotechnology · 2024Article
- Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with leptomeningeal metastases harboring targetable mutations.Translational lung cancer research · 2024Article
- A Comparative Analysis of NOX4 Protein Expression in Malignant and Non-Malignant Thyroid Tumors.Current issues in molecular biology · 2023Article
- Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid cells, crucial players in antitumoral defense, are affected by tumor-derived factors and treatment. The role of myeloid cells and their progenitors prior to tumor infiltration is poorly understood. Here we show single-cell transcriptomics and functional analyses of the myeloid cell lineage in patients with non-medullary thyroid carcinoma (TC) and multinodular goiter, before and after treatment with radioactive iodine compared to healthy controls. Integrative data analysis indicates that monocytes of TC patients have transcriptional upregulation of antigen presentation, reduced cytokine production capacity, and overproduction of reactive oxygen species. Interestingly, these cancer-related pathological changes are partially removed upon treatment. In bone marrow, TC patients tend to shift from myelopoiesis towards lymphopoiesis, reflected in transcriptional differences. Taken together, distinct transcriptional and functional changes in myeloid cells arise before their infiltration of the tumor and are already initiated in bone marrow, which suggests an active role in forming the tumor immune microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.